... targets, including Abl, c-kit and PDGFR kinases, showed minimal efficacy in early clinicaltesting with a small number of patients [19,20]. Identification of these preclinical candidate markers and ... R255ResearchIdentification of candidate predictive and surrogate molecular markers for dasatinib in prostate cancer: rationale for patient selection and efficacy monitoringXi-De Wang, Karen Reeves, ... Additionally, EphA2, a target of dasatinib, is a candidate predictor of efficacy in both prostate and breastcancer. Finally, the observed sensitivity to dasatinib of pros-tate cancer cell lines with...